Fundamental Data for VRTX

VERTEX PHA(NSDQ:VRTX)

Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)

# Employees: 1333

Address: 130 Waverly Street,Cambridge,MA,USA

Phone: 617 444-6100

Fax: 617 444-6680

Website: www.vpharm.com

Email: investorinfo@vrtx.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Joshua S. Boger Ph.D. (Chmn.; Presi.; C.E.O.)

Kenneth S. Boger (Sr. V.P.; Genl. Counsl.)

Richard C. Garrison Ph.D. (Sr. V.P.; Organizational Devlpt.)

Ian F. Smith CPA (Exec. V.P.; C.F.O.)

Victor A. Hartmann M.D. (Exec. V.P.; Medicines Devlpt.; Chief Medi. Off.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/8/2010

Mean EPS (Next Qtr): ($0.85)

Mean EPS (Year): ($3.68)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 21

Shares Performance

Period	VRTX	Compare to S&P
YTD	28.37 %	6.23 %
4 Weeks	16.21 %	10.32 %
12 Weeks	7.38 %	-0.01 %

Shares Information

Analyst Coverage: Y

Avg Volume: 2547520

Shares Outstanding: 180M

Market Cap: $7.05B

52 Week High: $41.10

52 Week Low: $21.21

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 8/24/2000 VRTX split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: 9.78 %

EPS Growth in Last Year: 10.75 %

Sales Growth in Last Quarter: 30.91 %

Sales Growth in Last Quarter: -21.04 %

Financials

Qtr Book Value: $11.57

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 69.350